Alembic Pharmaceuticals Limited (APLLTD) — Announcement | 26 June 2026

StockFin.ai

Try Free

📢 Key Event
Alembic Pharmaceuticals receives USFDA final approval for Oseltamivir Phosphate Oral Suspension 6 mg/mL

Alembic Pharmaceuticals announced USFDA final approval for Oseltamivir Phosphate Oral Suspension 6 mg/mL, a generic version of Tamiflu. The product targets a $27 million market and adds to Alembic's 243 ANDA approvals, including 223 final approvals. This regulatory milestone expands the company's antiviral portfolio and positions it for potential revenue growth in the US influenza treatment market.

📄 View Original Announcement (PDF)

📊 Stock Analysis — APLLTD ✨ Ask AI About This

About Alembic Pharmaceuticals Limited (APLLTD)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹15,412.51 Cr P/E: 22.9 ROE: 11.8% ROCE: 11.2%

View full APLLTD stock details →

📡 Get AI alerts when APLLTD files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track APLLTD — Free

💡 Ask AI about this filing

"How does this affect APLLTD margins?" "Compare with last quarter results" "What should investors watch for?"

Ask AI Free →

📊 More APLLTD filings

See all APLLTD filings →

🔥 Also filed on 26 June 2026

NRL Nupur Recyclers Limited Insider Trading BBL Bharat Bijlee Limited Annual Report BIRLACORPN Birla Corporation Limited Corporate Action BRIGADE Brigade Enterprises Limited Announcement NTPC NTPC Limited Announcement TTKPRESTIG TTK Prestige Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when APLLTD files new disclosures

Track APLLTD filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track APLLTD — Free

Free account · 2 AI queries/day